Tumor necrosis factor, cancer and anticancer therapy

被引:243
作者
Mocellin, S [1 ]
Rossi, CR [1 ]
Pilati, P [1 ]
Nitti, D [1 ]
机构
[1] Univ Padua, Policlin Univ, Dept Oncol & Surg Sci, I-35128 Padua, Italy
关键词
tumor necrosis factor (TNF); antineoplastic agent; antitumor therapy;
D O I
10.1016/j.cytogfr.2004.11.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor necrosis factor (TNF) is being utilized as an antineoplastic agent for the treatment of patients with locally advanced solid tumors. However, its role in cancer therapy is debated. Although a large body of evidence supports TNF's antineoplastic activity, the cascade of molecular events underlying TNF-mediated tumor regression observed in vivo is still incompletely elucidated. Intriguingly, some pre-clinical findings suggest that TNF may promote cancer development and progression, which has led to propose anti-TNF therapy as a novel approach to malignancies. In the present work, we summarize the molecular biology of TNF with particular regard to its tumor-related properties, and review the experimental and clinical evidence currently available describing the complex and sometime conflicting relationship between this cytokine, cancer and antitumor therapy. Recent insights that might pave the way to further exploitation of the antineoplastic potential of TNF are also discussed. (c) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:35 / 53
页数:19
相关论文
共 229 条
[1]   Signalling pathways of the TNF superfamily: A double-edged sword [J].
Aggarwal, BB .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (09) :745-756
[2]  
Aggarwal BB, 2000, ANN RHEUM DIS, V59, P6
[3]  
Alexander HR, 2000, CLIN CANCER RES, V6, P3062
[4]   Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver [J].
Alexander, HR ;
Bartlett, DL ;
Libutti, SK ;
Fraker, DL ;
Moser, T ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1479-1489
[5]   Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy [J].
Alexander, HR ;
Libutti, SK ;
Bartlett, DL ;
Pingpank, JF ;
Kranda, K ;
Helsabeck, C ;
Beresnev, T .
CANCER, 2002, 95 (04) :730-736
[6]  
Ameloot Paul, 2004, Methods Mol Med, V98, P33
[7]  
An JB, 2003, CLIN CANCER RES, V9, P4537
[8]   Tumor necrosis factor-α in the pathogenesis and treatment of cancer [J].
Anderson, GM ;
Nakada, MT ;
DeWitte, M .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (04) :314-320
[9]   Tumour necrosis factor-α mediates tumour promotion via a PKCα- and AP-1-dependent pathway [J].
Arnott, CH ;
Scott, KA ;
Moore, RJ ;
Hewer, A ;
Phillips, DH ;
Parker, P ;
Balkwill, FR ;
Owens, DM .
ONCOGENE, 2002, 21 (31) :4728-4738
[10]   Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development [J].
Arnott, CH ;
Scott, KA ;
Moore, RJ ;
Robinson, SC ;
Thompson, RG ;
Balkwill, FR .
ONCOGENE, 2004, 23 (10) :1902-1910